

FIGURE 1A





FIGURE 1B

FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6





FIGURE 7


FIGURE 8

FIGURE 9

CMT.64 Transfectants +/- VSV





FIGURE 10

FIGURE 11




FIGURE 12




FIGURE 14

TAP 1 versus TAP 2 CMT 64 Transfectants +/- VSV




FIGURE 15

CMT 64 Transfectants +/- VSV




FIGURE 16

CTL Response to Influenza




FIGURE 17

CTL Response to Influenza




FIGURE 18

CTL Response to Influenza




FIGURE 19

CTL Response to HSV-1




FIGURE 20

Survival of C57BL/6 and Balb/C Mice Injected with 5×10^5 CMT.64 or CMT.12.12





FIGURE 21

A



B





FIGURE 22

A



B





FIGURE 23

A



B

	VV-NP	VV-NP + VV-hTAP12
VSV pCTL	1/78,000	1/16,000

FIGURE 24




FIGURE 25




FIGURE 26




FIGURE 27




FIGURE 28




FIGURE 29






FIGURE 30**A****B**

FIGURE 31




FIGURE 32A




FIGURE 32B




FIGURE 33

TAP1 enhanced the presentation of VSV-NP by B16 cells




FIGURE 34

TAP1 enhanced the presentation of TRP-2 by B16 cells




FIGURE 35




FIGURE 36




FIGURE 37




FIGURE 38




FIGURE 39




FIGURE 40

